These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 21998474

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.
    Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.
    J Virol; 2017 Aug 01; 91(15):. PubMed ID: 28539438
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
    Kim S, Jang JE, Yu JR, Chang J.
    Vaccine; 2010 May 14; 28(22):3801-8. PubMed ID: 20362203
    [Abstract] [Full Text] [Related]

  • 9. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
    Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.
    Pediatr Infect Dis J; 2009 Sep 14; 28(9):835-7. PubMed ID: 19636278
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
    Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.
    Antimicrob Agents Chemother; 2016 Jan 14; 60(1):6-13. PubMed ID: 26438495
    [Abstract] [Full Text] [Related]

  • 12. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus.
    Fisher RG, Crowe JE, Johnson TR, Tang YW, Graham BS.
    J Infect Dis; 1999 Oct 14; 180(4):1324-7. PubMed ID: 10479165
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA.
    McGivney JB, Bishop E, Miller K, Casas-Finet J, Yang H, Wei Z, Strouse R, Schenerman M.
    J Pharm Biomed Anal; 2011 Feb 20; 54(3):572-6. PubMed ID: 20943340
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ.
    Vaccine; 2007 Jul 20; 25(29):5378-89. PubMed ID: 17561317
    [Abstract] [Full Text] [Related]

  • 16. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S.
    Virology; 2008 Aug 15; 378(1):79-85. PubMed ID: 18556039
    [Abstract] [Full Text] [Related]

  • 17. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 18. [Research Progress in the F Gene and Protein of the Respiratory Syncytial Virus].
    Zhang F, Xie Z.
    Bing Du Xue Bao; 2015 Mar 04; 31(2):201-6. PubMed ID: 26164949
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.
    Fisher RG, Johnson JE, Dillon SB, Parker RA, Graham BS.
    J Infect Dis; 1999 Sep 04; 180(3):708-13. PubMed ID: 10438358
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, Dillon SB.
    Pediatr Res; 1995 Oct 04; 38(4):543-50. PubMed ID: 8559607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.